@FierceMedDev: Low-cost smart syringe shoots for reduced disease transmission. News | Follow @FierceMedDev
@VarunSaxena2: Ahead of Apple Watch launch, hearing aid company reveals its app development experience. Story | Follow @VarunSaxena2
@EmilyWFierce: Medical device makers such as $GE, $ABT, $BSX and $JNJ forming the first industry trade group in #Asia. Pharmalot story | Follow @EmilyWFierce
> Spectranetics ($SPNC) is beefing up investments in its drug-coated balloon for peripheral artery disease, eyeing a market estimated to grow to $150 million by 2020. More
> Brainlab is planning to roll out a new generation of stereotactic radiosurgery (SRS) planning devices for spinal radiosurgery at next week's ESTRO conference in Barcelona. Release
> MIT-spinoff Empatica is developing a medical device, dubbed Embrace, which includes a real-time stress indicator that can predict the onset of epileptic seizures. More
> Piramal Imaging is funneling cash into a new clinical study to see how well its FDA-approved diagnostic radiotracer can scan for beta-amyloid buildup in the brain. Statement
Biotech News
@FierceBiotech: AstraZeneca loans its oncology star to Celgene, recruits Innate in a PD-L1 deal spree. News | Follow @FierceBiotech
@JohnCFierce: Aerie shares crushed after glaucoma therapy flops in PhIII. Story | Follow @JohnCFierce
> Biogen ($BIIB) blueprints a big Phase III effort for its Alzheimer's hopeful. Article
> Regeneron ($REGN), Alnylam ($ALNY) help drive a $2B spike in biotech R&D spending. More
> Sanofi ($SNY) dumps an ImmunoGen ($IMGN) cancer drug as it scales back in oncology. News
Pharma News
@FiercePharma: Labeling foul-up involving acetaminophen leads RB to recall 135 lots of Mucinex. News | Follow @FiercePharma
@EricPFierce: Bayer to close a vet med plant in Missouri it bought from Teva. 130 workers to lose jobs. Article | Follow @EricPFierce
@CarlyHFierce: ICYMI: Watch out, Big Pharma: A Teva-Mylan combo would remake the industry Top 10. Story | Follow @CarlyHFierce
> Bristol-Myers Squibb ($BMS) scores positive EMA opinion for Opdivo in advanced melanoma patients. More
> AstraZeneca ($AZN) sales retreat in its effort to achieve huge growth by 2023. News